Newsroom & Stories

NEWSROOM

News & Stories

Gene Assay for MammaPrint May Predict Responses to Extended Letrozole in Low-Risk Breast Cancer Subsets
By Roman Fabbricatore | August 30, 2024 A gene assay was predictive of response to extended letrozole therapy, identifying a subset of patients with low-risk breast cancer with improved Read More
Personalized Breast Cancer Treatment Offered by Texas Breast Center Utilizes Agendia
Texas Breast Center, led by renowned breast surgeon Dr. Valerie Gorman, is pleased to announce the use of Agendia, a global leader in genomic testing. This collaboration aims to Read More
Hormonal Therapy Story: How Laura-Lynn Renner Made an Informed Choice
By Kris Conner | August 7, 2024 How the diagnostic test MammaPrint empowered Laura-Lynn to find answers and advocate to improve the quality of her life. In the summer Read More

Newsroom

Press Releases

German Gynecological Oncology Group (AGO) includes BluePrint® in Guidelines

Karen Guzdzial2024-08-05T13:34:45-04:00

German Gynecological Oncology Group (AGO) Recognizes BluePrint® in Breast Cancer Guidelines

Read More

Agendia Announces New I-SPY2 Data Showcasing Ability of New Signature ImPrintTN

Karen Guzdzial2024-07-18T11:07:34-04:00

Agendia Announces New Data from I-SPY 2 Showcasing Ability of New Signature ImPrintTN to Predict Immunotherapy Response in Patients with Triple Negative Breast Cancer

Read More

Agendia Presents Data from FLEX Study at Miami Breast 2024

Karen Guzdzial2024-09-27T17:54:41-04:00

Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrint® + BluePrint®’s Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens

Read More

Previous 234 Next

Newsroom

News, Stories & Breast Cancer Blog

Fierce Healthcare: Biden’s ‘Cancer Moonshot’ is already being fueled by tech addressing breast cancer

Joel Adamich2024-10-07T15:10:11-04:00

Fierce Healthcare recently spoke with Nathalie Johnson, MD, FACS, President of The American Society of Breast Cancer Surgeons, about the need for more widespread use of advanced gene expression profiling tests that provide more consistent results for Black women with early-stage breast cancer. Dr. Johnson highlights how the standard of care today negatively impacts outcomes for Black women, and why it is essential for clinicians to switch to more sophisticated, unbiased tests, such as MammaPrint & BluePrint, to address key disparities in breast cancer care.

Read the Article

Previous 23